Related Experiment Video
Updated: Dec 15, 2025
In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver
Published on: May 4, 2016
16.1K
FDA Oncology Center of Excellence Review Processes and Tools
Jennifer J Gao1, Paul G Kluetz1, Richard Pazdur1
1Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland, USA.
Clinical Pharmacology and Therapeutics
|July 13, 2020
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.
Clinical cancer research : an official journal of the American Association for Cancer Research·2025
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research·2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.
Clinical cancer research : an official journal of the American Association for Cancer Research·2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Advanced Non-small Cell Lung Cancer.
Clinical pharmacology and therapeutics·2026
Exposure-Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First-Line Therapy for Locally Advanced or Metastatic Urothelial Cancer.
Clinical pharmacology and therapeutics·2026
Constructing an External Control Arm Using the French REALYSA Cohort to Replicate Outcomes of a Randomized Trial Arm in Advanced Hodgkin Lymphoma.
Clinical pharmacology and therapeutics·2026
Toward Fit-for-Purpose Data for Drug Assessment in Non-small Cell Lung Cancer: A Core Dataset.
Clinical pharmacology and therapeutics·2026
Construction and application of mammary and breast cancer organoids.
Cell insight·2026
Comparative Phenotypic and Molecular Characterisation of Feline Oral Squamous Cell Carcinoma Cell Lines Reveals Marked Biological Heterogeneity.
Veterinary and comparative oncology·2026
Metabolic regulation of tumor angiogenesis in colorectal cancer: mechanisms and therapeutic opportunities.
Biochimica et biophysica acta. Reviews on cancer·2026
Curcumin inhibits atherosclerotic plaque formation by regulating PLCG2 ubiquitination in vascular smooth muscle cells.
International immunopharmacology·2026
Neuroimmune crosstalk in pancreatic ductal adenocarcinoma: integrating neuroscience and immuno-oncology.
International immunopharmacology·2026